Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC gynecological cancer cooperative group study

J. V Th H Hamerlynck, A. P. Maskens, C. Mangioni, M. E L van der Burg, J. A M J Wils, J. B. Vermorken, N. Rotmensz

Research output: Contribution to journalArticle

Abstract

Progestin therapy of ovarian carcinoma in the past has been reported to lead to varying response rates. A multicenter phase II study of high-dose MPA was conducted in 53 patients with epithelial ovarian cancer who had received adequate trials of conventional therapy with cytotoxic agents. Forty-one patients were included for response and toxicity evaluations. Only one partial response has been recorded with a duration of 20 weeks. Stabilization of disease was observed in 7 patients. The present investigation shows that MPA given at the present high dose is not effective in patients extensively pretreated with chemotherapy.

Original languageEnglish
Pages (from-to)313-316
Number of pages4
JournalGynecologic Oncology
Volume22
Issue number3
DOIs
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC gynecological cancer cooperative group study'. Together they form a unique fingerprint.

  • Cite this

    Hamerlynck, J. V. T. H., Maskens, A. P., Mangioni, C., van der Burg, M. E. L., Wils, J. A. M. J., Vermorken, J. B., & Rotmensz, N. (1985). Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC gynecological cancer cooperative group study. Gynecologic Oncology, 22(3), 313-316. https://doi.org/10.1016/0090-8258(85)90045-9